Everything below concerns fatty acid oxidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
=== Occurrence in space === Nitriles are among the most abundant organic molecules in space, and more than ten distinct compounds have been unequivocally detected. Hydrogen cyanide was one of the first polyatomic species identified in space and occurs there relatively frequently and in substantial quantities. Other nitriles detected in space include acetonitrile and aminoacetonitrile, as well as butyronitrile, cyanoacetylene, and cyanopolyins containing two to five conjugated triple bonds. Hydrogen cyanide, cyanoacetylene, and cyanogen are present in the atmosphere of Saturn's moon Titan.
=== Mechanism === RIP causes G:C to A:T transition mutations within repeats, however, the mechanism that detects the repeated sequences is unknown. RID is the only known protein essential for RIP. It is a DNA methyltransferease-like protein, that when mutated or knocked out results in loss of RIP. Deletion of the rid homolog in Aspergillus nidulans, dmtA, results in loss of fertility while deletion of the rid homolog in Ascobolus immersens, masc1, results in fertility defects and loss of methylation induced premeiotically (MIP).
1985–1987 – 1.3 L (1,296 cc) E3, 2 barrel, 8-valve, 74 PS (54 kW; 73 hp) Gross / 10.5 kg⋅m (103 N⋅m; 76 lb⋅ft) 1987–1989 – 1.3 L (1,323 cc) B3, 2 barrel, 8-valve, 67 PS (49 kW; 66 hp) Net / 10.4 kg⋅m (102 N⋅m; 75 lb⋅ft) 1985–1987 – 1.5 L (1,490 cc) E5, 2 barrel carburettor, 8-valve, 85 PS (63 kW; 84 hp) Gross / 12.3 kg⋅m (121 N⋅m; 89 lb⋅ft) Gross – Net rating 70 PS (51 kW; 69 hp) / 11.2 kg⋅m (110 N⋅m; 81 lb⋅ft) 1985–1987 – 1.5 L (1,490 cc) E5, EGi, 8-valve, 95 PS (70 kW; 94 hp) Gross/12.6 kg⋅m (124 N⋅m; 91 lb⋅ft) Gross – Net rating 76 PS (56 kW; 75 hp) / 11.6 kg⋅m (114 N⋅m; 84 lb⋅ft) 1985–1987 – 1.5 L (1,490 cc) E5T, turbo EGi, 8-valve, 115 PS (85 kW; 113 hp) Gross / 16.5 kg⋅m (162 N⋅m; 119 lb⋅ft) 1987–1989 – 1.5 L (1,498 cc) B5, 2 barrel, 12-valve, 76 PS (56 kW; 75 hp) Net / 11.4 kg⋅m (112 N⋅m; 82 lb⋅ft) 1987–1989 – 1.6 L (1,597 cc) B6, EGi, 8-valve, 85 PS (63 kW; 84 hp) Net / 12.5 kg⋅m (123 N⋅m; 90 lb⋅ft) 1986–1989 – 1.6 L (1,597 cc) B6D, EGi, 16-valve, 110 PS (81 kW; 108 hp) Net / 13.5 kg⋅m (132 N⋅m; 98 lb⋅ft) 1985–1989 – 1.6 L (1,597 cc) B6T, turbo EGi, 16-valve, 140 PS (103 kW; 138 hp) Net / 19.0 kg⋅m (186 N⋅m; 137 lb⋅ft) 1985–1989 – 1.7 L (1,720 cc) PN, diesel, 8-valve, 59 PS (43 kW; 58 hp) Gross / 10.8 kg⋅m (106 N⋅m; 78 lb⋅ft) Gross – Net rating 55 PS (40 kW; 54 hp) / 10.2 kg⋅m (100 N⋅m; 74 lb⋅ft), 1987–1989; Net rating: 58 PS (43 kW; 57 hp) / 10.7 kg⋅m (105 N⋅m; 77 lb⋅ft)
=== An–At === Rudolph John Anderson (1879–1961). American biochemist graduated with a PhD from Cornell University Medical College. Member Natl. Acad. Sci. USA. Thomas F. Anderson (1911–1991). American biophysical chemist and geneticist at the University of Pennsylvania, a pioneer in applying electron microscopy to bacteria and viruses. Member Natl. Acad. Sci. USA. Mortimer Louis Anson (1901–1968). American biochemist and protein chemist, the first to propose that protein folding was reversible. Akira Arimura (1923–2007). Japanese biochemist and endocrinologist at Tulane University who studied hormones. Shy Arkin (b. 1965). Israeli biochemist at the Hebrew University of Jerusalem, working on structural analysis of transmembrane proteins Judy Armitage FRS (b. 1951). British biochemist at Oxford University, working on motion of bacteria by flagellar rotation. Frances Arnold (b. 1956). American biochemist and biochemical engineer at Caltech, pioneer of the use of directed evolution to engineer enzymes. Nobel Prize for Chemistry (2018). Member Natl. Acad. Sci. USA. Ruth Arnon (b. 1933) Israeli biochemist at the Weizmann Institute, who works on researching anti-cancer and influenza vaccinations. She participated in developing the multiple sclerosis drug Copaxone. President of the Israel Academy of Sciences and Humanities. Helen Asemota (20th–21st century). Nigerian biochemist at the University of the West Indies, Jamaica, who studied the molecular genetics and metabolism of the browning of yam tubers in storage. Gilbert Ashwell (1916–2014).
Sources: en.wikipedia.org
Dein described Wenger as the most important manager in the club's history: "Arsène's a miracle worker. He's revolutionised the club. He's turned players into world-class players. Since he has been here, we have seen football from another planet". Former Watford manager Graham Taylor said of Wenger in 2002: "I believe his biggest contribution to football is getting across the idea that players have to prepare right and look after themselves". Wenger's loyalty towards financial fair play and handling of Arsenal's debt since their stadium move has earnt him praise, not least from American baseball general manager Billy Beane, who in particular lauded his transfer strategy. A survey in 2007 found Wenger was the only Premier League manager to have made a profit on transfers, and between 2004 and 2009, he made an average profit of £4.4 million per season on transfers, far more than any other club.
On 8 April 2026, the United States and Iran agreed to a two-week ceasefire in the 2026 Iran war, mediated by Pakistan. Iran had rejected the draft proposal for a 45-day two-phase ceasefire framework introduced on 5 April by Pakistan, instead proposing its own 10-point plan for a peace agreement. The proposal was developed as part of ongoing mediation efforts involving regional and international actors during the 2025–2026 negotiations. Since its declaration, the ceasefire was violated by both sides numerous times. On 21 April, US president Donald Trump extended the ceasefire indefinitely. On 8 July, the ceasefire deal collapsed after attacks by both sides. Low-intensity fighting between the US and Iran continued intermittently. Later, Trump decided to arrive at a more comprehensive ceasefire that would lead to an US–Iranian agreement. As a result, new ceasefire conditions were agreed upon on 12 June. On 17 June, the presidents of both countries signed the Islamabad Memorandum, a memorandum of understanding that formalized the process of ending the war and established a 60-day period to negotiate the final terms of a deal.
=== General medical === Disorders of volume Injury can cause blood loss through bleeding. A healthy adult can lose almost 20% of blood volume (1 L) before the first symptom, restlessness, begins, and 40% of volume (2 L) before shock sets in. Thrombocytes are important for blood coagulation and the formation of blood clots, which can stop bleeding. Trauma to the internal organs or bones can cause internal bleeding, which can sometimes be severe. Dehydration can reduce the blood volume by reducing the water content of the blood. This would rarely result in shock (apart from the very severe cases) but may result in orthostatic hypotension and fainting. Disorders of circulation Shock is the ineffective perfusion of tissues, and can be caused by a variety of conditions including blood loss, infection, and poor cardiac output. Atherosclerosis reduces the flow of blood through arteries, because atheroma lines arteries and narrows them. Atheroma tends to increase with age, and its progression can be compounded by many causes including smoking, hypertension, excess circulating lipids (hyperlipidemia), and diabetes mellitus. Coagulation can form a thrombosis, which can obstruct vessels. Problems with blood composition, the pumping action of the heart, or narrowing of blood vessels can have many consequences including hypoxia (lack of oxygen) of the tissues supplied. The term ischemia refers to tissue that is inadequately perfused with blood, and infarction refers to tissue death (necrosis), which can occur when the blood supply has been blocked (or is very inadequate).
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.